Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brigitte C Widemann

Showing results (1-10 of 203) with videos related to

Pageof 21
Sort By:
Clinical Advances in Hematology & Oncology : H&O|July 25, 2013
Using a lower dose of glucarpidase to reduce plasma levels of methotrexateBrigitte C Widemann
Current Opinion in Pediatrics|January 2, 2023
Advances, challenges and progress in pediatric hematology and oncologyBrigitte C Widemann
Cancer Journal (Sudbury, Mass.)|March 6, 2004
Merlin PAKs a punchBrigitte C Widemann
The Lancet. Oncology|November 30, 2019
Immune checkpoint inhibitors for refractory childhood cancersBrigitte C Widemann
Pediatric Blood & Cancer|October 22, 2015
Reply to: Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate ExcretionBrigitte C Widemann
Current Opinion in Pediatrics|December 19, 2024
Advances in pediatric oncology through collaborationsBrigitte C Widemann
Current Oncology Reports|June 11, 2009
Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumorsBrigitte C Widemann
Pediatric Blood & Cancer|May 6, 2015
Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunctionBrigitte C Widemann
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2017
Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and PerspectivesBrigitte C Widemann, Antoine Italiano
The Oncologist|June 24, 2006
Understanding and managing methotrexate nephrotoxicityBrigitte C Widemann, Peter C Adamson
Pageof 21

Showing results (1-10 of 203) with videos related to

Sort By:
Pageof 21
Clinical Advances in Hematology & Oncology : H&O|July 25, 2013
Using a lower dose of glucarpidase to reduce plasma levels of methotrexateBrigitte C Widemann
Current Opinion in Pediatrics|January 2, 2023
Advances, challenges and progress in pediatric hematology and oncologyBrigitte C Widemann
Cancer Journal (Sudbury, Mass.)|March 6, 2004
Merlin PAKs a punchBrigitte C Widemann
The Lancet. Oncology|November 30, 2019
Immune checkpoint inhibitors for refractory childhood cancersBrigitte C Widemann
Pediatric Blood & Cancer|October 22, 2015
Reply to: Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate ExcretionBrigitte C Widemann
Current Opinion in Pediatrics|December 19, 2024
Advances in pediatric oncology through collaborationsBrigitte C Widemann
Current Oncology Reports|June 11, 2009
Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumorsBrigitte C Widemann
Pediatric Blood & Cancer|May 6, 2015
Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunctionBrigitte C Widemann
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2017
Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and PerspectivesBrigitte C Widemann, Antoine Italiano
The Oncologist|June 24, 2006
Understanding and managing methotrexate nephrotoxicityBrigitte C Widemann, Peter C Adamson
Pageof 21